Written answers
Tuesday, 21 May 2019
Department of Health
Medicinal Products Availability
Mary Lou McDonald (Dublin Central, Sinn Fein)
Link to this: Individually | In context | Oireachtas source
408. To ask the Minister for Health if the HSE Leadership Team met on 14 May 2019 to consider additional information submitted by the manufacturer of the drug Spinraza; and when the team will make a final decision on the reimbursement of the drug based on this information. [21754/19]
Eoin Ó Broin (Dublin Mid West, Sinn Fein)
Link to this: Individually | In context | Oireachtas source
452. To ask the Minister for Health the outcome of the HSE Leadership Team meeting on 14 May 2019 with respect to the issue of Spinraza; and when the drug will be made available to those that need it. [22020/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 408 and 452 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the pricing and reimbursement of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments